Edmond DE Rothschild Holding S.A. reduced its stake in shares of Natera, Inc. (NASDAQ:NTRA – Free Report) by 28.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,700 shares of the medical research company’s stock after selling 3,800 shares during the quarter. Edmond DE Rothschild Holding S.A.’s holdings in Natera were worth $4,009,000 as of its most recent SEC filing.
Several other hedge funds have also modified their holdings of the company. SYM FINANCIAL Corp boosted its position in shares of Natera by 1.7% in the 3rd quarter. SYM FINANCIAL Corp now owns 1,897 shares of the medical research company’s stock worth $784,000 after purchasing an additional 32 shares in the last quarter. Versant Capital Management Inc grew its position in Natera by 4.6% during the 3rd quarter. Versant Capital Management Inc now owns 815 shares of the medical research company’s stock worth $337,000 after purchasing an additional 36 shares during the last quarter. AlphaCentric Advisors LLC raised its holdings in shares of Natera by 3.0% in the third quarter. AlphaCentric Advisors LLC now owns 1,432 shares of the medical research company’s stock worth $592,000 after buying an additional 42 shares during the last quarter. VestGen Advisors LLC raised its stake in Natera by 3.1% in the 3rd quarter. VestGen Advisors LLC now owns 1,460 shares of the medical research company’s stock worth $603,000 after acquiring an additional 44 shares during the last quarter. Finally, Parallel Advisors LLC grew its stake in Natera by 5.5% during the 1st quarter. Parallel Advisors LLC now owns 905 shares of the medical research company’s stock valued at $181,000 after purchasing an additional 47 shares during the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.
Natera Stock Performance
Shares of NTRA stock opened at $273.08 on Friday. The stock’s fifty day moving average is $375.51 and its two-hundred day moving average is $272.97. Natera, Inc. has a fifty-two week low of $181.00 and a fifty-two week high of $437.41.
Natera (NASDAQ:NTRA – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The medical research company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.14). The business had revenue of $793.98 million during the quarter, compared to analysts’ expectations of $707.54 million. Natera had a negative return on equity of 8.61% and a negative net margin of 5.66%. The business’s quarterly revenue was up 34.1% on a year-over-year basis. During the same period in the prior year, the business posted ($0.64) earnings per share. On average, equities analysts predict that Natera, Inc. will post -1.21 earnings per share for the current year.
Insider Activity
In other Natera news, CEO Steven Chapman sold 3,801 shares of the firm’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $411.80, for a total transaction of $1,565,251.80. Following the completion of the sale, the chief executive officer owned 87,431 shares of the company’s stock, valued at $36,004,085.80. This trade represents a 4.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Michael Brophy sold 1,906 shares of the stock in a transaction on Friday, October 30th. The stock was sold at an average price of $425.55, for a total value of $811,098.30. Following the transaction, the chief financial officer owned 46,574 shares of the company’s stock, valued at approximately $19,819,565.70. This represents a 3.93% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 47,056 shares of company stock valued at $17,760,989. 5.05% of the stock is currently owned by insiders.
Analyst Upgrades and Downgrades
NTRA has been the topic of several research reports. JPMorgan Chase & Co. cut their price target on shares of Natera from $460.00 to $405.00 and set an “overweight” rating on the stock in a report on Friday, November 6th. BTIG Research upped their target price on Natera from $320.00 to $430.00 and gave the stock a “buy” rating in a research note on Tuesday, October 27th. Wells Fargo & Company lifted their price target on Natera from $220.00 to $284.00 and gave the company an “equal weight” rating in a research report on Friday, August 7th. Royal Bank Of Canada boosted their target price on shares of Natera from $350.00 to $460.00 and gave the company an “outperform” rating in a research note on Friday, September 25th. Finally, Canaccord Genuity Group lifted their price objective on shares of Natera from $375.00 to $500.00 and gave the company a “buy” rating in a report on Monday, October 19th. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $396.93.
Get Our Latest Research Report on Natera
Natera Profile
Natera, Inc. is a diagnostics company that develops and provides genetic testing and molecular diagnostics for reproductive health, oncology and organ health. Its tests analyze cell-free DNA and other genetic material to support screening, diagnosis and disease monitoring. In reproductive health, Natera offers Panorama, a noninvasive prenatal screening test, and Horizon, a carrier screening test. Its oncology portfolio includes Signatera, a personalized circulating tumor DNA test used to monitor for molecular residual disease and assess cancer recurrence.
Recommended Stories
- Five stocks we like better than Natera
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA – Free Report).
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
